Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday,
GlobeNewswire16:30 ET
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8
GlobeNewswireApr 24 10:02 ET
CVS Favors Humira Copycats Hurting AbbVie's Market Share: Evercore
Seeking AlphaApr 17 09:26 ET
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)
TipRanksApr 15 04:30 ET
Unafraid of generic drugs entering the US market, ABBV.US (ABBV.US) Humira still accounts for nearly 100% of the share
Although a large number of discounted biosimilars entered the US market more than a year ago, ABBV.US (ABBV.US)'s blockbuster arthritis drug Humira (adalimumab) continues to maintain nearly 100% of the market share.
Zhitong FinanceApr 15 02:24 ET
Investors in Coherus BioSciences (NASDAQ:CHRS) Have Unfortunately Lost 83% Over the Last Five Years
Yahoo FinanceApr 11 07:05 ET
CNDT, CHRS and OM Are Among Materials Movers
Seeking AlphaApr 5 16:42 ET
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 20 07:28 ET
Express News | HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11
Moomoo 24/7Mar 20 07:19 ET
Buy Rating on Coherus Biosciences: Balancing Divestiture With Promising Pipeline and Financial Growth
TipRanksMar 20 06:16 ET
Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations
Yahoo FinanceMar 15 06:17 ET
Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating
TipRanksMar 15 01:36 ET
Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)
TipRanksMar 14 20:30 ET
Why Coherus Biosciences Stock Tumbled on Thursday
The Motley FoolMar 14 18:28 ET
Coherus BioSciences Shares Fall After Workforce Reduction Plan; Q4 Loss
Coherus BioSciences (CHRS) shares fell 5.7% in recent Thursday trading, a day after the biopharmaceutical firm said it expects to idle around 30% of its workforce by year end. Cehrus completed the $17
MT NewswiresMar 14 16:27 ET
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)
TipRanksMar 14 13:40 ET
Coherus Gains as Oncology Focus Leads to Job Cuts
Seeking AlphaMar 14 11:22 ET
Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target
Moomoo 24/7Mar 14 07:33 ET
Coherus BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 499.08% HC Wainwright & Co. → $13 Reiterates Buy → Buy 01/23/2024 314.75% Baird $11 → $9 Mainta
BenzingaMar 14 07:31 ET
Buy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic Restructuring
TipRanksMar 14 06:15 ET
No Data
No Data